Objective
METAFORA develops a disruptive blood-based In Vitro Diagnostic platform called METAdiag, METAdiag monitors cells’ energetic needs thanks to unique, proprietary biomarkers (Receptor Binding Domains or RBDs), able to quantify nutrient transporters used by cells to feed on glucose, amino acids, vitamins and other essential nutrient transporters at the cell’s surface.
Cutting edge algorithms using Artificial Intelligence to handle big data participate in generating actionable results to physicians for routine clinical practice,
METAglut1 is a first test developed to fill a medical unmet need, i.e.: the easy and early diagnosis of a debilitating but curable neuro-metabolic disease in children, GLUT1 Deficiency Syndrome. METAglut1 test’s positive results have been published in a leading scientific journal, has been CE-marked and is at the basis of a partnering agreement with CERBA Healthcare, a leading Medical Testing Laboratory.
Next steps include:
o A large scale validation study in Europe to secure the reimbursement of the test
o Downsizing of the test as a finger prick blood test
o Dissemination of METAglut1 in Europe big 5 countries (Germany, UK, France, Italy and Spain) and North America via business development effort and market access
o Extension of the test application to newborn screening in the USA
Following the validation and commercial launch of this first test, next applications to come out of the METAdiag platform include a breakthrough test enabling the diagnosis and therapeutic monitoring of cancers, with a market launch contemplated 3 years after the Phase 2 project ends,
METAFORA anticipates cumulative revenues of over €52M and 75 jobs created 5 years after the commercialization of our first test, and ambitions to become a key player in the IVD market.
Fields of science
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
75014 PARIS
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.